TG Therapeutics, Inc. $TGTX Shares Purchased by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 65.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,673 shares of the biopharmaceutical company’s stock after purchasing an additional 12,503 shares during the quarter. Maryland State Retirement & Pension System’s holdings in TG Therapeutics were worth $1,767,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in TGTX. Jacobi Capital Management LLC purchased a new position in TG Therapeutics in the 3rd quarter valued at $57,000. Illinois Municipal Retirement Fund grew its holdings in shares of TG Therapeutics by 15.1% during the third quarter. Illinois Municipal Retirement Fund now owns 67,221 shares of the biopharmaceutical company’s stock worth $3,750,000 after buying an additional 8,824 shares in the last quarter. Lido Advisors LLC grew its holdings in shares of TG Therapeutics by 6.8% during the third quarter. Lido Advisors LLC now owns 20,613 shares of the biopharmaceutical company’s stock worth $1,150,000 after buying an additional 1,308 shares in the last quarter. New York Life Investment Management LLC acquired a new stake in shares of TG Therapeutics in the third quarter valued at about $1,222,000. Finally, Allspring Global Investments Holdings LLC raised its position in shares of TG Therapeutics by 36.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 310,856 shares of the biopharmaceutical company’s stock valued at $16,668,000 after buying an additional 83,426 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Trading Down 0.1%

NASDAQ TGTX traded down $0.05 on Friday, reaching $64.51. 1,095,871 shares of the company were exchanged, compared to its average volume of 2,131,002. The company has a current ratio of 4.50, a quick ratio of 3.72 and a debt-to-equity ratio of 1.30. The business’s fifty day moving average price is $56.69 and its 200 day moving average price is $45.33. The stock has a market capitalization of $9.75 billion, a P/E ratio of 97.74, a price-to-earnings-growth ratio of 5.08 and a beta of 1.89. TG Therapeutics, Inc. has a fifty-two week low of $26.76 and a fifty-two week high of $68.03.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The company had revenue of $259.94 million during the quarter, compared to analyst estimates of $245.47 million. During the same period last year, the business earned $2.43 earnings per share. The firm’s revenue was up 60.8% compared to the same quarter last year. Analysts forecast that TG Therapeutics, Inc. will post 1.10 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the transaction, the director owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 8.87% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TGTX shares. B. Riley Financial raised their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. HC Wainwright reiterated a “buy” rating and issued a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, September 1st. Weiss Ratings upgraded shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, November 4th. Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Research upgraded TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

Check Out Our Latest Report on TG Therapeutics

TG Therapeutics Company Profile

(Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Further Reading

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.